196604-62-3

Upstream product

• 153186-10-8 ((3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol 
• 196604-57-6 2'-O-acetyl-3',5'-di-O-benzyl-4'-C-fluoromethyluridine 
• 200066-88-2 1-((2R,3R,4S,5R)-4-Benzyloxy-5-benzyloxymethyl-5-fluoromethyl-3-hydroxy-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione 
• 196604-56-5 1,2-di-O-acetyl-3,5-di-O-benzyl-4-C-fluoromethyl-D-ribofuranose 
• 196604-54-3 3,5-di-O-benzyl-4-C-fluoromethyl-1,2-O-isopropylidene-α-D-ribofuranose 

Downstream Products

• 1445381-19-0 1-((2R,3R,4R,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-3-fluoro-5-(fluoromethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 

Relevant academic research and scientific papers

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTICS COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Synthesis of 4'-C-fluoromethylnucleosides as potential antineoplastic agents

2-Deoxy-D-erythro-, ribo-, and arabino-pentofuranosylcytosines, which have a fluoromethyl group at the 4'-position, were synthesized. Introduction of fluorine was achieved by DAST treatment of 4-C-hydoxymethy]-D-ribofuranose, the key intermediate of 4'-C-methylnucleosides. Among these nucleosides, the 2'-deoxy derivative exhibited potent antineoplastic activity in vitro.